Searched for
EYESTEM RESEARCH
After deeptech firms, expect RDIF rollout for Indian VCs soonLast month, close to 20 Indian investors, which included Ideaspring Capital, Speciale Invest, Chiratae Ventures, Sixth Sense Ventures, and ...- Industry sees Budget 2026–27 as execution-oriented, capital-friendly, and future-readyLeaders across private equity, infrastructure, technology, real estate, telecom, and healthcare welcome the Budget’s focus on execution, ca...
- Eyestem receives CDSCO approval to initiate Phase 2 randomised, controlled human trials of Eyecyte-RPEEyestem Research has secured approval from India's CDSCO to begin Phase 2 clinical trials for its Eyecyte-RPE cell therapy. This treatment ...
- Eyestem’s Eyecyte-RPE trial shows vision rescue for geographic atrophy patientsEyestem will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy Innovation Summit in ...
- Eyestem completes first set of patient injections for Dry AMD treatmentEyestem Research has completed the first set of patient injections for its RPE suspension therapy aimed at treating Dry age-related macular...
- Advancing stem cell therapy: The regulatory process to get to clinical trialsAdvancements in new drug and stem cell therapy can transform the treatment of many diseases, but development is complicated, takes years an...
- Budget: Enabling sustainable and investment-led economic growthAchieving high resilient growth while ensuring sustainable and inclusive livelihood options for all remains a priority for India. The inter...
- Eyestem partners with RetinAI for treatment of geographic atrophy with AI techGeographic atrophy can lead to irreversible loss of vision over time and currently affects 200 million people globally.
- Affordable gene and cell therapies need of the hour: Dr Kapil Bharti, Scientific Director, National Eye InstituteLimitless potential for future global advancements in gene therapies is originating from India, said Dr David Gamm.
- Eyestem files for IND approval for its product to treat geographic atrophyEyestem Research has announced the submission of IND application to CDSCO to start first in-human trials of Eyecyte-RPE™for subjects.
- Why India's promising biotech industry needs more attentionIndia's biotechnology industry has a promising future ahead, however, it is still lacking the interest of investors.
- ET Startup Awards on Saturday; profitability a must for IPO-bound companies: Accel’s Shekhar KiraniTop entrepreneurs, policymakers and investors will come together in Bengaluru on November 19 to celebrate the eighth edition of The Economi...
- ET Startup Awards 2022: Razorpay edges out peers, bags top prizeAt a virtual meeting that lasted for more than two hours on October 28, a high-powered jury led by Infosys CEO and MD Salil Parekh picked t...
- ET Startup Awards 2022: Eyestem bags the Top Innovator awardEyestem’s aim to treat “incurable” eye diseases helped it pip Haber, an artificial intelligence powered startup that simplifies manufacturi...
- Why are investors shying away from biotech startups?Investors have largely been risk-averse when it comes to deep-funding biotech startups that have the potential to turn into billion-dollar ...
- Incubated at C-CAMP, seven deeptech startups have raised more than Rs 550 croreC-CAMP is one of the largest biotech ecosystems in India and a global hub for innovations led by deep-tech.
- Eyestem raises Series A round from Biological E, Alkem and othersThe investment will enable Eyestem to progress a treatment for Dry Age-related Macular Degeneration to the clinic.
- Cell therapy startup Eyestem raises ₹51 crore from BE, Alkem & NatcoExisting investors Endiya Partners and Kotak Private Equity also participated in this round, valuing Eyestem at $46.4 million (INR 371 Cror...
- India all set for the biotech bounce among its startupsA new set of deep science startups is delving into subjects as diverse as medicine, energy and agri to lay the foundation for a large biote...
Load More
